{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:05Z","timestamp":1787026505035,"version":"build-2736575974"},"reference-count":90,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00805"],"award-info":[{"award-number":["PI18\/00805"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.euroneuro.2019.09.007","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T07:46:29Z","timestamp":1570175189000},"page":"1199-1212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Expert advice on the management of valproate in women with bipolar disorder at childbearing age"],"prefix":"10.1016","volume":"29","author":[{"given":"Gerard","family":"Anmella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Pacchiarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6343-8454","authenticated-orcid":false,"given":"Wies\u0142aw Jerzy","family":"Cuba\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Maina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8459-7742","authenticated-orcid":false,"given":"Pierre","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0053","authenticated-orcid":false,"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2019.09.007_bib0088","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/AOG.0b013e31816fd910","article-title":"Practice bulletin No. 92: use of psychiatric medications during pregnancy and lactation. The American College of Obstetricians and Gynecologists (ACOG)","volume":"111","year":"2008","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0001","series-title":"Valproato: Programa de Prevenci\u00f3n de Embarazos","year":"2018"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0002","series-title":"Comunicaci\u00f3n para Profesionales Sanitarios \u2013 Valproato: Nuevas Restricciones de uso; Puesta en Pr\u00e1ctica del Programa de Prevenci\u00f3n de Embarazos","year":"2018"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0003","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PSY.0b013e318190d7ca","article-title":"ECT in pregnancy: a review of the literature from 1941 to 2007","volume":"71","author":"Anderson","year":"2009","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0004","article-title":"Major congenital malformations associated with exposure to antiepileptic drugs during pregnancy","volume":"79","author":"Andrade","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1034\/j.1399-5618.1999.10106.x","article-title":"Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications","volume":"1","author":"Baldessarini","year":"1999","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0006","doi-asserted-by":"crossref","unstructured":"Bergink, V.K., 2014. Lithium During Pregnancy.","DOI":"10.1176\/appi.ajp.2014.14030409"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0007","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1176\/appi.ajp.2012.11071047","article-title":"Prevention of postpartum psychosis and mania in women at high risk","volume":"169","author":"Bergink","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0008","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1399-5618.2007.00389.x","article-title":"Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study","volume":"9","author":"Biel","year":"2007","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0009","article-title":"Impact of a prenatal episode and diagnosis in women with serious mental illnesses on neonatal complications (prematurity, low birth weight, and hospitalization in neonatal intensive care units)","author":"Boukakiou","year":"2018","journal-title":"Arch. Women's Ment. Health"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1034\/j.1399-5618.2003.00031.x","article-title":"Valproate","volume":"5","author":"Bowden","year":"2003","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0011","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jad.2016.12.001","article-title":"Psychopharmacological drug utilization patterns in pregnant women with bipolar disorder \u2013 a nationwide register-based study","volume":"210","author":"Broeks","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0012","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1212\/01.wnl.0000339399.64213.1a","article-title":"AUTISM spectrum disorders following in utero exposure to antiepileptic drugs","volume":"71","author":"Bromley","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0013","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0014","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","article-title":"Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis","volume":"378","author":"Cipriani","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0015","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1176\/appi.ajp.2013.13010006","article-title":"Lamotrigine dosing for pregnant patients with bipolar disorder","volume":"170","author":"Clark","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0016","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1176\/ajp.152.11.1641","article-title":"Postpartum prophylaxis for women with bipolar disorder","volume":"152","author":"Cohen","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0017","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.yebeh.2011.06.014","article-title":"Fetal antiepileptic drug exposure: motor, adaptive, and emotional\/behavioral functioning at age 3years","volume":"22","author":"Cohen","year":"2011","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0018","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1192\/bjp.bp.107.040485","article-title":"Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial","volume":"194","author":"Colom","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0019","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40263-018-0517-5","article-title":"The safety of second-generation antipsychotics during pregnancy: a clinically focused review","volume":"32","author":"Damkier","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00023210-200822040-00004","article-title":"Pregnancy outcome after in utero exposure to valproate","volume":"22","author":"Diav-Citrin","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0021","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/01.pra.0000351878.45260.94","article-title":"Use and safety of antipsychotic drugs during pregnancy","volume":"15","author":"Einarson","year":"2009","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0022","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/DHPS.S50556","article-title":"Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges","volume":"7","author":"Epstein","year":"2014","journal-title":"Drug. Healthc. Patient Saf."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0023","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/pds.3366","article-title":"Increasing use of atypical antipsychotics and anticonvulsants during pregnancy","volume":"22","author":"Epstein","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0024","unstructured":"European Medicines Agency, 2019. EMA\/33617\/2014 \u2013 Rev.3. Questions & answers on Article 31 pharmacovigilance referral procedures."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0025","unstructured":"European Medicines Agency, 2018a. EMA\/375438\/2018. New measures to avoid valproate exposure in pregnancy endorsed."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0026","unstructured":"European Medicines Agency, 2018b. EMA\/198940\/2018, Pharmacovigilance Risk Assessment Committee (PRAC). Assessment report."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0027","unstructured":"European Medicines Agency, 2018c. EMA\/67672\/2018. PRAC recommends new measures to avoid valproate exposure in pregnancy."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0028","unstructured":"European Medicines Agency, 2017. EMA\/616811\/2017. Summary of the EMA public hearing on valproate in pregnancy Summary of the EMA public hearing on valproate in pregnancy Background information on the procedure."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0029","unstructured":"European Medicines Agency, 2014. European Medicines Agency. Assessment report. Procedure under Article 31 of Directive 2001\/83\/EC resulting from pharmacovigilance data."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0030","first-page":"180","article-title":"The international college of neuro-psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines","volume":"20","author":"Fountoulakis","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0031","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12916-018-1193-5","article-title":"Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births","volume":"16","author":"Gao","year":"2018","journal-title":"BMC Med."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0032","doi-asserted-by":"crossref","first-page":"223","DOI":"10.12740\/PP\/105906","article-title":"Adverse outcomes during pregnancy and major congenital malformations in infants of patients with bipolar and schizoaffective disorders treated with antiepileptic drugs: a systematic review","volume":"53","author":"Gim\u00e9nez","year":"2019","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0033","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0269881116636545","article-title":"Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British association for psychopharmacology","volume":"30","author":"Goodwin","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0034","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","article-title":"Bipolar disorder","volume":"387","author":"Grande","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0035","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1017\/S1461145713001168","article-title":"Antipsychotic switching in bipolar disorders: a systematic review","volume":"17","author":"Grande","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0036","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1017\/S1461145712000405","article-title":"Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES).","volume":"16","author":"Grande","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0037","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.4088\/JCP.12r07966","article-title":"Antidepressant exposure during pregnancy and congenital malformations: is there an association?","volume":"74","author":"Grigoriadis","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0038","doi-asserted-by":"crossref","first-page":"E1085","DOI":"10.1503\/cmaj.170088","article-title":"Perinatal suicide in Ontario, Canada: a 15-year population-based study","volume":"189","author":"Grigoriadis","year":"2017","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0039","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0165-0327(99)00197-4","article-title":"Protective effect of pregnancy in women with lithium-responsive bipolar disorder","volume":"61","author":"Grof","year":"2000","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/15622975.2013.770551","article-title":"The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder","volume":"14","author":"Grunze","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0089","author":"Hale","year":"2017","journal-title":"Medications & Mothers\u2019 Milk: a Manual of Lactational Pharmacology"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0041","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2012.12060828","article-title":"Unplanned pregnancies in adolescents with bipolar disorder","volume":"169","author":"Heffner","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0042","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jamapsychiatry.2016.1520","article-title":"Antipsychotic use in pregnancy and the risk for congenital malformations","volume":"73","author":"Huybrechts","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0043","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/00048670701732723","article-title":"Preliminary findings from the national register of antipsychotic medication in pregnancy","volume":"42","author":"Kulkarni","year":"2008","journal-title":"Aust. New Zeal. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/acps.12479","article-title":"Use of psychotropic drugs during pregnancy and breast-feeding","volume":"132","author":"Larsen","year":"2015","journal-title":"Acta Psychiatr. Scand"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0045","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/0004867415617657","article-title":"Royal australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders","volume":"49","author":"Malhi","year":"2015","journal-title":"Aust. New Zeal. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0046","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jad.2019.07.040","article-title":"Predictors and outcomes of suicidal ideation during peripartum period","volume":"257","author":"Martini","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0047","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.seizure.2012.01.005","article-title":"Valproate and the risk for congenital malformations: is formulation and dosage regime important?","volume":"21","author":"Mawhinney","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0048","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/0269881117699361","article-title":"British association for psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017","volume":"31","author":"McAllister-Williams","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0049","unstructured":"Mcevoy, J.P., Scheifler, P.L., Frances, A., 1999. The Journal of Clinical Psychiatry the Expert Consensus Guideline Series."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0050","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(11)61516-X","article-title":"Lithium toxicity profile: a systematic review and meta-analysis","volume":"379","author":"McKnight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0051","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0052","unstructured":"Medicines and Healthcare products Regulatory Agency, 2018. Valproate medicines (Epilim\u25bc, Depakote\u25bc): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy \u2013 GOV.UK \u2013 Government Digital Service Prevention Program are met [WWW Document]. URLhttps:\/\/www.gov.uk\/drug-safety-update\/valproate-medicines-epilim-depakote-contraindicated-in-women-and-girls-of-childbearing-potential-unless-conditions-of-pregnancy-prevention-program-are-met(accessed 3.25.19)."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0053","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S2215-0366(14)70314-1","article-title":"Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis","volume":"1","author":"Miura","year":"2014","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0054","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/0004867418762057","article-title":"Guidelines on treatment of perinatal depression with antidepressants: an international review","volume":"52","author":"Molenaar","year":"2018","journal-title":"Aust. New Zeal. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0055","first-page":"1","article-title":"Antipsychotic switching in schizoaffective disorder: a systematic review","volume":"17","author":"Murru","year":"2015","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0056","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11920-015-0603-z","article-title":"Management of adverse effects of mood stabilizers","volume":"17","author":"Murru","year":"2015","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0057","series-title":"Antenatal and Postnatal Mental Health: Antenatal and Postnatal Mental Health: Clinical Management and Service Clinical Management and Service Guidance Guidance Clinical Guideline","year":"2014"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0058","series-title":"Bipolar Disorder the Nice Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care Updated Edition","year":"2014"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0059","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jad.2011.10.015","article-title":"New treatment guidelines for acute bipolar mania: a critical review","volume":"140","author":"Nivoli","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020450","article-title":"A UK clinical audit addressing the quality of prescribing of sodium valproate for bipolar disorder in women of childbearing age","volume":"8","author":"Paton","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0061","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa1612222","article-title":"Lithium use in pregnancy and the risk of cardiac malformations","volume":"376","author":"Patorno","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0062","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1017\/S0033291709992340","article-title":"Mind-mindedness and maternal responsiveness in infant\u2013mother interactions in mothers with severe mental illness","volume":"40","author":"Pawlby","year":"2010","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0063","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00213-010-2056-8","article-title":"Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder","volume":"213","author":"Popovic","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0064","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.euroneuro.2011.09.008","article-title":"Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder","volume":"22","author":"Popovic","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0065","first-page":"63","article-title":"Maternal and fetal outcomes after lamotrigine use in pregnancy: a retrospective analysis from an urban maternal mental health centre in New Zealand","volume":"46","author":"Prakash","year":"2016","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0066","doi-asserted-by":"crossref","first-page":"263","DOI":"10.12740\/PP\/103555","volume":"53","author":"Rybakowski","year":"2019","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0067","doi-asserted-by":"crossref","first-page":"277","DOI":"10.12740\/PP\/104440","volume":"53","author":"Rymaszewska","year":"2019","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0068","doi-asserted-by":"crossref","first-page":"245","DOI":"10.12740\/PP\/103385","volume":"53","author":"Samochowiec","year":"2019","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0069","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2174\/157488611798918656","article-title":"Considerations in the pharmacotherapy of bipolar disorder during and after pregnancy","volume":"6","author":"Sharma","year":"2011","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0070","unstructured":"The Royal College of Psychiatrists, 2018. PS04\/18. Withdrawal of, and alternatives to, valproate-containing medicines in girls and women of childbearing potential who have a psychiatric illness."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0071","unstructured":"The Royal College of Psychiatrists, 2016. Prescribing valproate for bipolar disorder POMH-UK Quality Improvement Program. Topic 15a: baseline audit Prepared by the Prescribing Observatory for Mental Health-UK for Coventry and Warwickshire Partnership Trust - 26\/04\/2016."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0072","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00737-013-0330-6","article-title":"Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001\u20132007: a population-based study of 585,615 deliveries NIH public access","volume":"16","author":"Toh","year":"2013","journal-title":"Arch. Women's Ment. Health"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0073","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","article-title":"Teratogenicity of antiepileptic drugs","volume":"32","author":"Tomson","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0074","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/epi.13437","article-title":"Withdrawal of valproic acid treatment during pregnancy and seizure outcome: observations from EURAP","volume":"57","author":"Tomson","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0075","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0076","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","article-title":"Teratogenicity of antiepileptic drugs","volume":"32","author":"Tomson","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0077","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0090","year":"2015","journal-title":"Pregnancy and Lactation Labeling (Drugs) Final Rule"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0078","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1212\/WNL.0b013e3182a43e81","article-title":"Dose dependence of fetal malformations associated with valproate","volume":"81","author":"Vajda","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0079","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-017-0845-1","article-title":"Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes","volume":"15","author":"Veroniki","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0080","doi-asserted-by":"crossref","first-page":"18008","DOI":"10.1038\/nrdp.2018.8","article-title":"Bipolar disorders","volume":"4","author":"Vieta","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0081","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1176\/appi.ajp.2007.06101639","article-title":"Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation","volume":"164","author":"Viguera","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0082","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ajp.2015.15010124","article-title":"Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis","volume":"173","author":"Wesseloo","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0083","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child","volume":"11","author":"Weston","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0084","doi-asserted-by":"crossref","first-page":"k1609","DOI":"10.1136\/bmj.k1609","article-title":"Dangers of valproate in pregnancy","volume":"361","author":"Wieck","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0085","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/ajmg.a.35438","article-title":"Antiepileptic drugs and pregnancy outcomes","volume":"158A","author":"Wlodarczyk","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0086","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2019.09.007_bib0087","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/AOG.0b013e31821187a7","article-title":"Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women","volume":"117","author":"Yonkers","year":"2011","journal-title":"Obstet. Gynecol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X19308818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X19308818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:54:13Z","timestamp":1760378053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X19308818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":90,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0924977X19308818"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2019.09.007","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert advice on the management of valproate in women with bipolar disorder at childbearing age","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2019.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}